DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 04/08/2019 --Nonalcoholic Steatohepatitis (NASH) - Epidemiology and Market Forecast-2028

08 April 2019

The NASH market will experience significant annual growth as sales increase up to USD 3,096.1 million by 2027.
1. Diabetes population will significantly increase the prevalent cases of non- alcoholic fatty liver disease (NAFLD), with the CAGR of 1.02% for the study period i.e. 2016-2027 in the 7MM.
2. Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH.
3. NASH highest prevalence in the United States is almost 50% of the total prevalent cases, followed by Japan. Among all the 7MM countries, Spain had the lowest prevalent population.

(Albany, US) DelveInsight launched a new report on Nonalcoholic Steatohepatitis - Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key benefits

1. NASH market report covers a descriptive overview and comprehensive insight of the Nonalcoholic Steatohepatitis epidemiology and NASH market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Nonalcoholic Steatohepatitis market report provides the insights on the current and emerging therapies.
3. NASH market report provides global historical and forecasted market covering drug outreach in 7 MM.
4. Nonalcoholic Steatohepatitis market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the NASH market.

"NAFLD prevalent cases are expected to increase throughout the study period [2016-2027], reaching nearly 47 million cases in 2027."

Considering the market outlook, the number of effective NASH treatment increases during the forecast period, the supportive therapies (off-label) market share will start to decrease from a peak of 100% in 2016 to ~11% in 2027. Elafibranor (Genfit) will be the first drug for the NASH treatment which will be targeting the NASH Fibrosis (F1, F2 & F3) patients and Obeticholic acid (OCA; Intercept Pharmaceutical) will give competition to Elafibranor. Intercept's OCA is expected to grab maximum market share, owing to its development to target all stages of NASH (F1 to F4), except F0 and with the increasing demand for therapies to treat advanced stage of NASH, i.e. cirrhosis.
Now, there is no approved therapy for the NASH treatment. So, several companies have shifted their focus towards the development of targeted drugs with novel mechanism of action. It can be expected that the launch of emerging therapies will fill the void treatment areas in the near future.

Companies Covered:

1. Genfit
2. Intercept Pharmaceuticals
3. Gilead Sciences
4. Tobira Therapeutics
5. Galmed Pharmaceuticals
6. Bristol-Myers Squibb
7. Cirius Therapeutics
8. Conatus Pharmaceuticals
And many others

Drugs covered:
1. Obeticholic acid (OCA)
2. Selonsertib
3. Emricasan
4. GR-MD-02
5. IMM-124E
And many others

Key Topics Covered

1. Key Insights
2. Non-Alcoholic Steatohepatitis Market Overview at a Glance
3. Non-Alcoholic Steatohepatitis Disease Background and Overview
4. NASH Epidemiology and Patient Population
5. 7MM Epidemiology
6. United States Epidemiology, EU5 Epidemiology, Japan Epidemiology
7. Non-Alcoholic Steatohepatitis Treatment Algorithm
8. Experts Opinions for Off-Label (Supportive Therapies) drugs for the treatment of NASH
9. Treatment Guidelines
11. Unmet needs
12. Key Cross Competitors
13. Emerging Drugs
14.1. Drug Description
14.2.7. Product Profile
15. Nonalcoholic Steatohepatitis (NASH): 7 Major Market Analysis
16. The United States: Market Outlook
17. EU5: Market Outlook
18. Japan: Market Outlook
19. Market Drivers
20. Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight